MD20150103A2 - Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10 - Google Patents

Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10

Info

Publication number
MD20150103A2
MD20150103A2 MDA20150103A MD20150103A MD20150103A2 MD 20150103 A2 MD20150103 A2 MD 20150103A2 MD A20150103 A MDA20150103 A MD A20150103A MD 20150103 A MD20150103 A MD 20150103A MD 20150103 A2 MD20150103 A2 MD 20150103A2
Authority
MD
Moldova
Prior art keywords
imidazo
triazine derivatives
pde10 inhibitors
pde10
inhibitors
Prior art date
Application number
MDA20150103A
Other languages
English (en)
Russian (ru)
Inventor
Томас Аллен Чаппи
Кристофер Джон Хелал
Бетани Лин Кормос
Джемисон Брайс ТАТТЛ
Патрик Роберт Верхоест
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of MD20150103A2 publication Critical patent/MD20150103A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Prezenta invenţie se referă la o clasă nouă de derivaţi ai triazinei, descrişi prin formula I de mai jos, în care A, X, R1, R2, R3 şi R4 sunt aşa cum sunt definiţi în descriere, precum şi la utilizarea acestor derivaţi ca inhibitori ai fosfodiesterazei 10 (PDE10).
MDA20150103A 2013-05-02 2014-04-23 Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10 MD20150103A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02
PCT/IB2014/060945 WO2014177977A1 (en) 2013-05-02 2014-04-23 Imidazo-triazine derivatives as pde10 inhibitors

Publications (1)

Publication Number Publication Date
MD20150103A2 true MD20150103A2 (ro) 2016-02-29

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150103A MD20150103A2 (ro) 2013-05-02 2014-04-23 Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10

Country Status (34)

Country Link
US (3) US8933224B2 (ro)
EP (1) EP2991989B1 (ro)
JP (1) JP6263606B2 (ro)
KR (1) KR101770905B1 (ro)
CN (1) CN105164134B (ro)
AP (1) AP2015008843A0 (ro)
AR (1) AR096161A1 (ro)
AU (1) AU2014261070A1 (ro)
BR (1) BR112015027760A8 (ro)
CA (1) CA2910759C (ro)
CL (1) CL2015003037A1 (ro)
CR (1) CR20150591A (ro)
CU (1) CU20150144A7 (ro)
DK (1) DK2991989T3 (ro)
DO (1) DOP2015000271A (ro)
EA (1) EA027936B1 (ro)
EC (1) ECSP15050110A (ro)
ES (1) ES2637816T3 (ro)
GE (1) GEP201706675B (ro)
HK (1) HK1213885A1 (ro)
MA (1) MA38559B1 (ro)
MD (1) MD20150103A2 (ro)
MX (1) MX2015015163A (ro)
NI (1) NI201500157A (ro)
NZ (1) NZ712949A (ro)
PE (1) PE20151940A1 (ro)
PH (1) PH12015502462A1 (ro)
SG (1) SG11201508201VA (ro)
TN (1) TN2015000490A1 (ro)
TW (1) TWI508966B (ro)
UA (1) UA111696C2 (ro)
UY (1) UY35547A (ro)
WO (1) WO2014177977A1 (ro)
ZA (1) ZA201508968B (ro)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2991989T3 (en) * 2013-05-02 2017-07-31 Pfizer IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS
WO2018047081A1 (en) 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
KR20220087474A (ko) * 2019-10-21 2022-06-24 에스케이바이오팜 주식회사 인지 장애의 예방, 경감 또는 치료, 또는 인지 기능 향상을 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
WO2008041571A1 (fr) 2006-09-26 2008-04-10 Kaneka Corporation Procédé de fabrication d'un ester d'acide bêta-hydroxy-alpha-aminocarboxylique optiquement actif
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2009025785A2 (en) 2007-08-21 2009-02-26 Merck & Co., Inc. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
CN102596961B (zh) * 2009-10-30 2015-12-02 詹森药业有限公司 咪唑并[1，2-b]哒嗪衍生物及其作为PDE10抑制剂的用途
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
CA2799926A1 (en) 2010-05-28 2011-12-01 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
WO2012114222A1 (en) 2011-02-23 2012-08-30 Pfizer Inc. IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DK2991989T3 (en) * 2013-05-02 2017-07-31 Pfizer IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS

Also Published As

Publication number Publication date
ECSP15050110A (es) 2017-08-31
US9145427B2 (en) 2015-09-29
NI201500157A (es) 2015-11-30
CL2015003037A1 (es) 2016-04-22
KR20160003234A (ko) 2016-01-08
TWI508966B (zh) 2015-11-21
PE20151940A1 (es) 2016-01-21
CN105164134A (zh) 2015-12-16
CA2910759A1 (en) 2014-11-06
ES2637816T3 (es) 2017-10-17
DK2991989T3 (en) 2017-07-31
BR112015027760A8 (pt) 2018-05-08
US20150080401A1 (en) 2015-03-19
US20140329820A1 (en) 2014-11-06
US9296761B2 (en) 2016-03-29
GEP201706675B (en) 2017-05-25
CA2910759C (en) 2018-01-16
DOP2015000271A (es) 2016-02-29
WO2014177977A1 (en) 2014-11-06
EP2991989B1 (en) 2017-06-28
MX2015015163A (es) 2016-02-22
KR101770905B1 (ko) 2017-08-23
US8933224B2 (en) 2015-01-13
HK1213885A1 (zh) 2016-07-15
UA111696C2 (uk) 2016-05-25
JP6263606B2 (ja) 2018-01-17
TW201506027A (zh) 2015-02-16
NZ712949A (en) 2017-04-28
AP2015008843A0 (en) 2015-11-30
MA38559B1 (fr) 2018-04-30
EA027936B1 (ru) 2017-09-29
UY35547A (es) 2014-11-28
TN2015000490A1 (fr) 2017-04-06
EP2991989A1 (en) 2016-03-09
CR20150591A (es) 2016-01-04
EA201591819A1 (ru) 2016-05-31
PH12015502462A1 (en) 2016-02-22
US20150353579A1 (en) 2015-12-10
ZA201508968B (en) 2017-11-29
CN105164134B (zh) 2017-09-22
SG11201508201VA (en) 2015-11-27
CU20150144A7 (es) 2016-04-25
JP2016517877A (ja) 2016-06-20
AU2014261070A1 (en) 2015-10-29
AR096161A1 (es) 2015-12-09

Similar Documents

Publication Publication Date Title
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
NZ715838A (en) Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
MX2015010128A (es) Derivados de piridazinona macrociclicos.
PH12015501843A1 (en) Novel pyrazol derivatives
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
MX2015015786A (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas.
JO3318B1 (ar) مثبطات bace
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
PH12015502409B1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
PH12015502462A1 (en) Imidazo-triazine derivatives as pde10 inhibitors
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
MX2015011005A (es) Derivados de dihidorquinolin-2-ona para usarse como inhibidores de aldoesterona sintasa.
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).
IN2012DE00110A (ro)
MX2015009377A (es) Compuestos radiomarcados.
MX2016002762A (es) Derivados de fenil-dihidropiridina como inhibidores de aldosterona sintasa.

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)